Press Releases

Press Releases

Date Title and Summary Additional Formats
Toggle Summary Predictive Oncology Inc. Announces New CEO
MINNEAPOLIS , March 23, 2021 (GLOBE NEWSWIRE) -- Predictive Oncology (NASDAQ: POAI) , a knowledge-driven company focused on applying artificial intelligence to personalized medicine and drug discovery, is excited to announce today that they have appointed J.
View HTML
Toggle Summary Predictive Oncology Reports Year End 2020 Financial Results, Provides Business Update
MINNEAPOLIS , March 15, 2021 (GLOBE NEWSWIRE) -- Predictive Oncology (NASDAQ: POAI) – Predictive Oncology (Nasdaq: POAI) , a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, today reported financial results for the year ended
View HTML
Toggle Summary Predictive Oncology’s, Skyline Medical Division, Developing Generation 3 Direct-to-Drain Automated Fluid Waste Management System
MINNEAPOLIS , March 08, 2021 (GLOBE NEWSWIRE) -- Predictive Oncology (NASDAQ: POAI) , a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, announced today that its Skyline Medical Division is renewing developing a new Generation
View HTML
Toggle Summary POAI ‘s Helomics Division Announces Progress on Milestones for its AI-Driven Model of Ovarian Cancer
Helomics Researchers Complete Key Sequencing Milestones and Focus on AI-Driven Model Building MINNEAPOLIS , Feb. 24, 2021 (GLOBE NEWSWIRE) -- Predictive Oncology (NASDAQ: POAI) , a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug
View HTML
Toggle Summary Predictive Oncology Announces Closing of $17.6 Million Private Placement Priced At-the-Market
MINNEAPOLIS , Feb. 23, 2021 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ: POAI) (“Predictive Oncology” or “the Company”), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, today announced the closing of its previously
View HTML
Toggle Summary Predictive Oncology Announces $17.6 Million Private Placement Priced At-the-Market
MINNEAPOLIS , Feb. 18, 2021 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ: POAI) (“Predictive Oncology” or “the Company”), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, today that it has entered into securities
View HTML
Toggle Summary Two Top Researchers find Breakthrough Discoveries using Predictive Oncology’s Wholly Owned Subsidiary, TumorGenesis’s Technology
MINNEAPOLIS , Feb. 17, 2021 (GLOBE NEWSWIRE) -- Predictive Oncology (NASDAQ: POAI) , a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, announced today that the products of its wholly owned subsidiary, TumorGenesis, aided
View HTML
Toggle Summary Predictive Oncology Announces Closing of $7.4 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules
MINNEAPOLIS , Feb. 16, 2021 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ: POAI) (“Predictive Oncology” or “the Company”), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, today announced the closing of its previously
View HTML
Toggle Summary Predictive Oncology Announces $7.4 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules
MINNEAPOLIS , Feb. 10, 2021 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ: POAI) (“Predictive Oncology” or “the Company”), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, today announced that it has entered into
View HTML
Toggle Summary Predictive Oncology’s Wholly Owned Subsidiary Helomics announces the start of its drug repurposing project using its ground-breaking PeDAL™ platform for ovarian cancer
MINNEAPOLIS , Feb. 08, 2021 (GLOBE NEWSWIRE) -- Predictive Oncology (NASDAQ: POAI) , a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, announced today that it will start an in-house drug repurposing project, focused on ovarian
View HTML